Metropolis Healthcare Limited has informed the Exchange regarding a press release dated May 13, 2025, titled "Metropolis Healthcare reports Normalised PAT Growth of 26% for Full Year FY2024-25 and 24% in Q4FY25".
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare reported FY25 revenue of INR 1,331 Cr, up 12% year-on-year, driven by 6% growth in patient volumes and 7% growth in test volumes. Q4FY25 revenue grew 10% YoY to INR 345 Cr. Adjusted EBITDA for FY25 rose 14% to INR 325 Cr with margins expanding to 24.4%. Normalised PAT (excluding one-off acquisition and legal costs) grew 26% in FY25 to INR 161 Cr and 24% in Q4FY25 to INR 45 Cr. Reported PAT, however, fell 19% YoY in Q4FY25 to INR 29 Cr due to acquisition-related expenses, even though full-year reported PAT still grew 14% to INR 146 Cr. B2C revenue grew 17% in FY25 and B2B grew 12%, while TruHealth and specialty diagnostics remained the fastest-growing segments at 24% and 13% YoY respectively. The company added 29 new labs and 400 centres in FY25, expanding its footprint to 750+ towns.
Strong double-digit revenue and normalised profit growth signal healthy underlying business momentum, particularly in B2C and preventive testing. However, the sharp 19% drop in Q4 reported PAT due to acquisition and legal one-offs may draw investor attention in the short term; share price reaction will likely depend on how the market weighs the inorganic growth investments against near-term earnings.